Alnylam and Inceptive announced a $2B collaboration pairing 20 years of RNAi data with generative AI for siRNA discovery. This deal has profound implications for API development, tech transfer, and the pharmaceutical supply chain.

Novo Nordisk's semaglutide patent expired in India on March 20, 2026, triggering 50+ generic launches at up to 80% discounts. For API suppliers and CMO-CDMO partners, this patent cliff reshapes the global GLP-1 supply chain.

Alvotech and Teva FDA acceptance for AVT16, the first interchangeable biosimilar BLA for Entyvio vedolizumab, signals new biosimilar competition in IBD and creates manufacturing demand across biologics API and analytical services.

CordenPharma acquires peptide API specialist AmbioPharm, consolidating global peptide manufacturing across three continents to capture surging GLP-1 generic demand.